Malignant lymphoma: MR tomographic findings of residual mediastinal space-occupying lesions;Malignes lymphom: Magnetresonanztomographische befunde bei residuellen supradiaphragmalen raumfordernden lasionen

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 171, Issue 3, 1999, Pages 192-199

  Stroszczynski, Christian ^a   Hosten, N ^b   Oellinger, J ^b   Spahn, G ^b   Amthauer, H ^b   Bittner, R C ^b   Hierholzer, J ^b   Ludwig, W D ^b   Felix, R ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

Hodgkin's lymphoma, staging; Lymphoma, staging; MR

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; LYMPHOMA; MALE; MEDIASTINUM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOMA, HIGH-GRADE; MAGNETIC RESONANCE IMAGING; MALE; MEDIASTINAL NEOPLASMS; MEDIASTINUM; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PREDNISONE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VINCRISTINE;

EID: 0032888242     PISSN: 09366652     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Engert A, Tesch H, Wolf J, Diehl V: Chemotherapie der Hodgkin-Lymphome. Onkologe 1996; 2: 143-149
2. Hasenclever D, Loeffler M, Diehl V: Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996; 7: 95-98
3. Kaiser U, Trumper L, Pfreundschuh M, Havemann K: Behandlung aggressiver Non-Hodgkin-Lymphome. Internist 1997; 38: 135-142
4. Löffler M, Lathan B, Hasenclever D, Rüffler U, Petit M, Tesch H, Diehl V: Deutsche Hodgkin Lymphom Studiengruppe (Studien-protokolle der Primärtherapie). 3. Aufl. Hodgkin Studiensekretariat, Klinik I für Innere Medizin, Universität zu Köln Köln. Hodgkin Studiensekretariat 1995: 9-106
5. Tesch H, Sieber M, Diehl V: Hodgkin's disease. Treatment of intermediate stages. Baillieres Clin Haematol 1996; 9: 543-551
6. Savarese DMF, Hsieh CC, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997; 15: 2981-2995
7. Brado M, Betsch B, Brado B, Richter GM, Wunsch C, Nöldge G, Kauffmann GW: Maligne Lymphome. Diagnostik und Nachsorge beim Erwachsenen unter besonderer Berücksichtigung der Schnittbildverfahren. Radiologe 1997; 37: 10-18
8. Cabanillas F, Fuller LM: The radiologic assessment of the lymphoma patient from the standpoint of the clinician. Rad Clin N Amer 1990; 28: 683-695
9. North LB, Fuller LM, Sullivan-Halley JA, Hagemeister JB: Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology 1987; 164: 599-602
10. Stroszczynski C, Amthauer H, Hosten N, Mapara M, Ricke J, Jochens R, Fischer-Funk E, Ludwig WD, Eichstädt H, Felix R: Einsatz der Ga-67-SPECT bei Patienten mit malignen Lymphomen nach primärer Chemotherapie für die weitere Therapieplanung: Vergleich mit der Spiral-CT. Fortschr Röntgenstr 1997; 167: 458-467
11. Döhner H, Gückel F, Knauf W, Semmler W, van Kaick G, Ho AD, Himstein W: Magnetic resonance imaging of bone marrow in lymphoproliferative disorders: correlation with bone marrow biopsy. Brit J Haemat 1989; 73: 12-17
12. Heindel W, du Mesnil de Rochemont R, Kugel H, Ernst S, Tesch H, Diehl V, Lackner K: 31P-MR-Spektroskopie der menschlichen Leber - spektrale Hinweise auf eine Lymphominfiltration. Fortschr Röntgenstr 1997; 167: 62-70
13. Versluis PJ, Lamers RJ, van Belle AF: Primäres malignes Lymphom des Herzens: CT und MRT Befunde (Primary malignant lymphoma of the heart: CTand MRT features). Fortschr Röntgenstr 1995; 162: 533-534
14. Lorenzen J, Lorenzen M, Beese MS, Nicolas V: Magnetresonanz-tomographie bei malignen Lymphomen des weiblichen Beckens. Fortschr Röntgenstr 1996; 165: 602-604
15. Front D, Ben-Haim S, Israel O, Epelbaum R, Haim N, Even-Sapir E, Kolodny GM, Robinson E: Lymphoma: Predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182: 359-363
16. Front D, Israel O, Epelbaum R, Haim SB, Sapir EE, Jerushalmi J, Kolodny GM, Robinson E: Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175: 515-519
17. Radford JA, Cowan RA, Flangan M: The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940-946
18. Cohen-Hauguenauer A, Brice P, Gaci M: Apport de la scintigraphie au gallium-67 dans les lymphomes malins. La Presse Medicale 1993; 11: 521-525
19. Israel O, Front D, Lam M: Gallium 67 Imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 2439-2443
20. Hill M, Cunningham D, McVicar D, Roldan A, Husband J: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11: 2273-2278
21. Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E: Magnetic resonance imaging and Ga-67 scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. MAGMA 1996; 4: 213-224
22. Brice P, Rain JD, Frija J: Value of imaging for the diagnosis of residual mediastinal mass in malignant lymphomas. Nouv Rev Fr hematol 1991; 33: 531-532
23. Gasparini MD, Balzarini L, Castellani MR, Tess JT, Maffioli JS, Petrillo R, Ceglia E, Musumeci R, Buraggi GL: Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72: 577-582
24. Abrahamsen AF, Lien HH, Aas M, Winderen M, Hager B, Kvaloy S, Elgjio RF, Nome O: Magnetic resonance imaging and Gallium-67 scan in mediastinal malignant lymphoma: a prospective pilot study. Ann Oncol 1994; 5: 433-436
25. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G: comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8: 53-56
26. Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske SN: Vortäuschung eines mediastinalen Non-Hodgkin-Lymphomrezidives durch diffuse Thymushyperplasie im 18-F-FDG-PET. Fortschr Röntgenstr 1996; 165: 309-310
27. 3)deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 1985; 26: 278-282
28. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA: Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631-1637
29. Paul R: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67-citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288-292
30. Bumann D, de Wit M, Beyer W, Beese M, Lübeck M, Bücheler E, Clausen M: Computertomographie und F-18-FDG-Positronen-Emissions-Tomographie im Staging maligner Lymphome: ein Vergleich. Fortschr Röntgenstr 1998; 168: 457-465